Systematic review of the clinical effectiveness of genotropin (somatropin) in children with short stature

Journal of Pediatric Endocrinology and Metabolism

Volumn 23, Issue 6, 2010, Pages 535-551

  Loftus, Jane ^a   Heatley, Rebecca ^b   Walsh, Claire ^b   Dimitri, Paul ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b Evidence Research Unit   (United Kingdom)

^c SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Children; Genotropin; Growth hormone; Short stature; Systematic review

Indexed keywords

ETHINYLESTRADIOL; GONADORELIN AGONIST; HUMAN GROWTH HORMONE; PLACEBO; SONOMIT; UBIDECARENONE; UNCLASSIFIED DRUG;

AORTA DISSECTION; BODY COMPOSITION; BODY HEIGHT; BODY MASS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; EOSINOPHILIA; GROWTH RATE; HEMATOMA; HORMONAL THERAPY; HUMAN; INJECTION SITE HEMATOMA; INJECTION SITE REACTION; LOW DRUG DOSE; PRESCHOOL CHILD; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHOOL CHILD; SCOLIOSIS; SHORT STATURE; SIDE EFFECT; SYSTEMATIC REVIEW; THYROIDITIS; TREATMENT OUTCOME;

EID: 77954461959     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/jpem.2010.092     Document Type: Review

References (110)

1. Baxter L, Bryant J, Cave CB, Milne R. Recombinant growth hormone for children and adolescents with Turner syndrome. Cochrane Database Syst Rev 2007; CD003887.
2. Bryant J, Cave C, Mihaylova B, Chase D, McIntyre L, Gerard K, Milne R. Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. Health Technol Assess 2002; 6: 1-168.
3. Vimalachandra D, Hodson EM, Willis NS, Craig JC, Cowell C, Knight JF. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev 2006; 3: CD003264.
4. Child Growth Foundation. Growth hormone deficiency. Available at: http://www.childgrowth foundation.org/ghd.htm. Accessed 27 September 2009.
5. Traggiai C, Stanhope R. Management of growth hormone deficiency in children and adults. 2007; Prescriber 67-71.
6. Illig R. Growth hormone antibodies in patients treated with different preparations of human growth hormone (HGH). J Clin Endocrinol Metab 1970; 31: 679-688.
7. Colao A, Di SC, Spiezia S, Savastano S, Rota F, Savanelli MC, Lombardi G. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab 2008; 93: 3416-3424.
8. Janssen YJ, Doombos J, Roelfsema F. Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84: 279-284.
9. Kemp S. Growth hormone deficiency. Available at: http://emedicine. medscape.com/article/923688. Accessed 14 January 2009.
10. Sartorio A, Agosti F, De CA, Mazzilli G, Marazzi N, Busti C, Galli R, Lafortuna CL. Muscle strength and power, maximum oxygen consumption, and body composition in middle-aged short-stature adults with childhood-onset growth hormone deficiency. Arch Med Res 2008; 39: 78-83.
11. Wuster C. Fracture rates in patients with growth hormone deficiency. Horm Res 2000; 54 Suppl 1: 31-35.
12. Lagrou K, Xhrouet-Heinrichs D, Massa G, Vandeweghe M, Bourguignon JP, De SJ, de ZF, Emould C, Heinrichs C, Malvaux P, Craen M. Quality of life and retrospective perception of the effect of growth hormone treatment in adult patients with childhood growth hormone deficiency. J Pediatr Endocrinol Metab 2001; 14 Suppl 5: 1249-1260.
13. Sheppard L, Eiser C, Davies HA, Carney S, Clarke SA, Urquhart T, Ryder MJ, Stoner A, Wright NP, Butler G. The effects of growth hormone treatment on health-related quality of life in children. Horm Res 2006; 65: 243-249.
14. Cardiff Research Consortium. Growth hormone Delphi panel workshop overview. 2008.
15. Cassidy SB, Driscoll DJ. Prader-Willi syndrome. Eur J Hum Genet 2009; 17: 3-13.
16. Burd L, Vesely B, Martsolf J, Kerbeshian J. Prevalence study of Prader-Willi syndrome in North Dakota. Am J Med Genet 1990; 37: 97-99. (Pubitemid 20261357)
17. Vogels A, Van Den EJ, Keymolen K, Mortier G, Devriendt K, Legius E, Fryns JP. Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur J Hum Genet 2004; 12: 238-240. (Pubitemid 38499983)
18. Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer H. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 2001; 38: 792-798. (Pubitemid 33032939)
19. Paterson WF, Donaldson MD. Growth hormone therapy in the Prader-Willi syndrome. Arch Dis Child 2003; 88: 283-285.
20. Festen D-AM, van Toorenenbergen A, Duivenvoorden HJ, Hokken K. Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy. J Clin Endocrinol Metab 2007; 92: 1549-1554.
21. Nixon GM, Brouillette RT. Sleep and breathing in Prader-Willi syndrome. Pediatr Pulmonol 2002; 34: 209-217.
22. Patel S, Harmer JA, Loughnan G, Skilton MR, Steinbeck K, Celermajer DS. Characteristics of cardiac and vascular structure and function in Prader-Willi syndrome. Clin Endocrinol 2007; 66: 771-777.
23. Pfizer Australia PTY Limited. Somatropin (Genotropin®): PBAC Resubmission. 2007.
24. National Institute for Health and Clinical Excellence. Technology Assessment Report commissioned by the NHS R&D HTA programme on behalf of the National Institute for Health and Clinical Excellence - Final Protocol. 2008.
25. Saenger P. Turner's syndrome. N Engl J Med 1996; 335: 1749-1754.
26. Sybert VP, McCauley E. Turner's syndrome. N Engl J Med 2004; 351: 1227-1238.
27. Donaldson MD, Gault EJ, Tan KW, Dunger DB. Optimising management in Turner syndrome: from infancy to adult transfer. Arch Dis Child 2006; 91: 513-520.
28. Rovet J, Holland J. Psychological aspects of the Canadian randomized controlled trial of human growth hormone and low-dose ethinyl oestradiol in children with Turner syndrome. The Canadian Growth Hormone Advisory Group. Horm Res 1993; 39 Suppl 2: 60-64.
29. Johnston D, I, Betts P, Dunger D, Barnes N, Swift PG, Buckler JM, Butler GE. A multicentre trial of recombinant growth hormone and low dose oestrogen in Turner syndrome: near final height analysis. Arch Dis Child 2001; 84: 76-81.
30. Betts PR, Butler GE, Donaldson MD, Dunger DB, Johnston DI, Kelnar CJ, Kirk J, Price DA, Wilton P. A decade of growth hormone treatment in girls with Turner syndrome in the UK. UK KIGS Executive Group. Arch Dis Child 1999; 80: 221-225.
31. Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001. Pediatrics 2003; 111: 1253-1261.
32. Rapaport R, Tuvemo T. Growth and growth hormone in children born small for gestational age. Acta Paediatr 2005; 94: 1348-1355.
33. Saenger P, Czernichow P, Hughes I, Reiter EO. Small for gestational age: short stature and beyond. Endocr Rev 2007; 28: 219-251.
34. Lewis M, Shaw J, Reid C, Evans J, Webb N, Verrier-Jones K. Demography and management of childhood established renal failure in the UK (chapter 13). Nephrol Dial Transplant 2007; 22 Suppl 7: vii165-vii175.
35. National Institute of Health and Clinical Evidence. Guidance on the use of human growth hormone (somatropin) in children with growth failure. Technology Appraisal Guidance No 42 2002.
36. Bertella L, Mori I, Grugni G, Pignatti R, Ceriani F, Molinari E, Ceccarelli A, Sartorio A, Vettor R, Semenza C. Quality of life and psychological well- being in GH-treated, adult PWS patients: a longitudinal study. J Intellect Disabil Res 2007; 51: 302-311.
37. Christensen TL, Djurhuus CB, Clayton P, Christiansen JS. An evaluation of the relationship between adult height and health-related quality of life in the general UK population. Clin Endocrinol 2007; 67: 407-412.
38. Wales G, Bailey L, Eiser C, Wright N, Butler G. GH treatment and quality of life: the practicalities of running a multi-centre research study. BSPED, Swansea, UK, November 2008.
39. Wooten N, Bakalov VK, Hill S, Bondy CA. Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab 2008; 93: 2109-2114.
40. Hauffa BP. One-year results of growth hormone treatment of short stature in Prader-Willi syndrome. Acta Paediatr Suppl 1997; 53-55.
41. Lindgren AC, Hagenas L, Muller J, Blichfeldt S, Rosenborg M, Brismar T, Ritzen EM. Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: a preliminary report. The Swedish National Growth Hormone Advisory Group. Acta Paediatr Suppl 1997; 423: 60-62.
42. Lindgren AC, Hagenas L, Muller J, Blichfeldt S, Rosenborg M, Brismar T, Ritzen EM. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. Acta Paediatr 1998; 87: 28-31. (Pubitemid 28086601)
43. Chaussain JL, Colle M, Landier F. Effects of growth hormone therapy in prepubertal children with short stature secondary to intrauterine growth retardation. Acta Paediatr Suppl 1992; 399: 74-75.
44. Coelho R, Brook CG, Preece MA, Stanhope RG, Dattani MT, Hindmarsh PC. A randomised study of two doses of biosynthetic human growth hormone on final height of pubertal children with growth hormone deficiency. Horm Res 2008; 70: 85-88.
45. Dörr HG, Zabransky S, Keller E, Otten BJ, Partsch CJ, Nyman L, Gillespie BK, Lester NR, Wilson AM, Hyrén C, van Kuijck MA, Schuld P, Schoenfeld SL. Are needle-free injections a useful alternative for growth hormone therapy in children? Safety and pharmacokinetics of growth hormone delivered by a new needle-free injection device compared to a fine gauge needle. J Pediatr Endocrinol Metab 2003; 16: 383-392.
46. Romer T, Peter F, Saenger P, Starzyk J, Koehler B, Korman E, Walczak- M, Wasik R, Ginalska MM, Solyom E, Berghout A. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution. J Endocrinol Invest 2007; 30: 578-589.
47. Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr 2004; 145: 744-749. (Pubitemid 39586610)
48. Eiholzer U, Allemand D, Schlumpf M, Rousson V, Gasser T, Fusch C. Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome. J Pediatr 2004; 144: 753-758.
49. Festen D-AM, Visser TJ, Often BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega A-CS. Thyroid hormone levels in children with Prader-Willi syndrome before and during growth hormone treatment. Clin Endocrinol 2007; 67: 449-456.
50. Festen DA, de Lind van WR, van EM, Often BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega AC. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader- Willi syndrome. Clin Endocrinol 2008; 69: 443-451.
51. Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, LaFranchi SH. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab 2003; 88: 2206-2212.
52. Myers SE, Whitman BY, Carrel AL, Moerchen V, Bekx MT, Allen DB. Two years of growth hormone therapy in young children with Prader- Willi syndrome: physical and neurodevelopmental benefits. Am J Med Genet 2007; 143: 443-448.
53. Roderick FA, van Wijngaarden d, de Klerk LWL, Festen DAM, Often BJ, Hokken-Koelega ACS. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. clin endocrinol metab 2009; Epub ahead of print.
54. Whitman B, Carrel A, Bekx T, Weber C, Allen D, Myers S. Growth hormone improves body composition and motor development in infants with Prader-Willi syndrome after six months. J Pediatr Endocrinol Metab 2004; 17: 591-600. (Pubitemid 38931055)
55. Broyer M. Results and side-effects of treating children with growth hormone after kidney transplantation - a preliminary report. Pharmacia & Upjohn Study Group. Acta Paediatr Suppl 1996; 417: 76-79. (Pubitemid 27115752)
56. Boguszewski M, Albertsson WK, Aronsson S, Gustafsson J, Hagenäs L, Westgren U, Westphal O, Lipsanen NM, Sipilä I, Gellert P, Müller J, Madsen B. Growth hormone treatment of short children born small-for-gestational- age: the Nordic Multicentre Trial. Acta Paediatr 1998; 87: 257-263.
57. Bozzola E, Lauriola S, Messina MF, Bona G, Tinelli C, Tatò L. Effect of different growth hormone dosages on the growth velocity in children born small for gestational age. Horm Res 2004; 61: 98-102. (Pubitemid 38316479)
58. Bundak R, Darendeliler F, Günöz H, Bas c, Saka N, Neyzi O. Growth hormone treatment in short children with intrauterine growth retardation. J Pediatr Endocrinol Metab 2001; 14: 313-318.
59. Butenandt O, Lang G. Recombinant human growth hormone in short children born small for gestational age. German Study Group. J Pediatr Endocrinol Metab 1997; 10: 275-282. (Pubitemid 27254982)
60. Carrascosa A, Esteban C, Espadero R, Fernández CM, Andaluz P, Clemente M, Audí L, Wollmann H, Fryklund L, Parodi L. The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients. J Clin Endocrinol Metab 2006; 91: 3281-3286.
61. De Schepper J, Thomas M, Beckers D, Craen M, Maes M, de ZF. Growth hormone treatment and fat redistribution in children born small for gestational age. J Pediatr 2008; 152: 327-330.
62. de Zegher F, Maes M, Heinrichs C, Thiry G, Du CM, V, De Schepper J, Craen M, Chanoine JP, Dooms L, Malvaux P. High-dose growth hormone therapy for short children born small for gestational age. Belgian Study Group for Paediatric Endocrinology. Acta Paediatr Suppl 1996; 399: 77.
63. de Zegher F, Ong K, van Helvoirt M, Mohn A, Woods- Katie, Dunger D. High-dose growth hormone (GH) treatment in non-GH-deficient children born small for gestational age induces growth responses related to pretreatment GH secretion and associated with a reversible decrease in insulin sensitivity. J Clin Endocrinol Metab 2002; 87: 148-151. (Pubitemid 34084684)
64. Lagrou K, Vanderfaeillie J, Froidecoeur C, Thomas M, Massa G, Tenoutasse S, Craen M, Lebrethon MC, Beckers D, Francois I, Rooman R, Thiry CG, de Beaufort C, De Schepper J. Effect of 2 years of high-dose growth hormone therapy on cognitive and psychosocial development in short children born small for gestational age. Eur J Endocrinol 2007; 156: 195-201.
65. Tanaka T, Matsuo N, Seino Y, Fujieda K, Yokoya S, Tachibana K. Growth-promoting and psychological effects of high-dose growth hormone treatment in children with intrauterine growth retardation. Clin Pediatr Endocrinol 2000; 9: 7-17.
66. Tanaka T, Fujieda K, Yokoya S, Seino Y, Tada H, Mishina J. Efficacy and safety of growth hormone treatment in children born small for gestational age in Japan. J Pediatr Endocrinol Metab 2008; 21: 423-431. (Pubitemid 351894990)
67. Van Erum R, Carels C, Verbeke G, de Zegher F. Craniofacial growth in short children born small for gestational age: two years follow-up after high-dose growth hormone treatment. J Craniofac Genet Dev Biol 1997; 17: 184-189. (Pubitemid 28045978)
68. Ankarberg LC, Norjavaara E, Wikland KA. Short boys treated with growth hormone show normal progression of testicular size and achieve normal serum testosterone concentrations. Eur J Endocrinol 2002; 146: 681-685. (Pubitemid 34552502)
69. Cole TJ, Hindmarsh PC, Dunger DB. Growth hormone (GH) provocation tests and the response to GH treatment in GH deficiency. Arch Dis Child Educ Pract Ed 2004; 89: 1024-1027.
70. Darendeliler F, Berberoglu M, Ocal G, Adiyaman P, Bundak R, Günöz H, Bas F, Darcan S, Göksen D, Arslanoglu I, Yildiz M, Ercan O, Ercan G, Ozerkan E, Can S, Böber E, Adal E, Sarikaya S, Dallar Y, Siklar Z, Bircan I, Bideci A, Yüksel B, Büyükgebiz A. Response to growth hormone with respect to pubertal status on increased dose in idiopathic growth hormone deficiency: an analysis of Turkish children in the KIGS database (Pfizer International Growth Study). J Pediatr Endocrinol Metab 2005; 18: 949-954.
71. Darendeliler F, Ranke MB, Bakker B, Lindberg A, Cowell CT, Albertsson WK, Reiter EO, Price DA. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: Analysis of data from KIGS (Pfizer International Growth Database). Horm Res 2005; 63: 40-47.
72. Donadieu J, Rolon MA, Pion I, Thomas C, Doz F, Barkaoui M, Robert A, Deville A, Mazingue F, David M, Brauner R, Cabrol S, Garel C, Polak M. Incidence of Growth Hormone Deficiency in Pediatric-Onset Langerhans Cell Histiocytosis: Efficacy and Safety of Growth Hormone Treatment. J Clin Endocrinol Metab 2004; 89: 604-609.
73. Geffner M, Lundberg M, Koltowska HM, Abs R, Verhelst J, Erfurth EM, Kendall TP, Price DA, Jonsson P, Bakker B. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: Analysis of KIGS (Pfizer International Growth Database). J Clin Endocrinol Metab 2004; 5435-5440.
74. Kjellberg H, Wikland KA. A longitudinal study of craniofacial growth in idiopathic short stature and growth hormone-deficient boys treated with growth hormone. Eur J Orthod 2007; 29: 243-250.
75. Lindgren AC, Chatelain P, Lindberg A, Price DA, Ranke MB, Reiter E, Wilton P. Normal progression of testicular size in boys with idiopathic short stature and isolated growth hormone deficiency treated with growth hormone: experience from the KIGS. Horm Res 2002; 58: 83-87.
76. Martin DD, Hauspie RC, Ranke MB. Total pubertal growth and markers of puberty onset in adolescents with GHD: comparison between mathematical growth analysis and pubertal staging methods. Horm Res 2005; 63: 95-101.
77. Ranke MB, Price DA, Lindberg A, Wilton P, Darendeliler F, Reiter EO. Final height in children with medulloblastoma treated with growth hormone. Horm Res 2005; 64: 28-34.
78. Ranke MB, Lindberg A, Albertsson WK, Wilton P, Price DA, Reiter EO. Increased response, but lower responsiveness, to Growth Hormone (GH) in very young children (aged 0-3 years) with idiopathic GH deficiency: Analysis of data from KIGS. J Clin Endocrinol Metab 2005; 90: 1966-1971.
79. Ranke MBE, Traunecker R, Martin DD, Schweizer R, Schwarze CP, Wollmann HA, Binder G. IGF-I and IGF binding protein-3 levels during initial GH dosage step- up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age. Horm Res 2005; 64: 68-76. (Pubitemid 41433917)
80. Reiter EO, Lindberg A, Ranke MB, Price DA, Albertsson WK, Cowell CT, Bakker B. The KIGS experience with the addition of gonadotropin- releasing hormone agonists to growth hormone (GH) treatment of children with idiopathic GH deficiency. Horm Res 2003; 60: 68-73.
81. Reiter EO, Price DA, Wilton P, Albertsson WK, Ranke MB. Effect of Growth Hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: Analysis of a large international database. J Clin Endocrinol Metab 2006; 91: 2047-2054.
82. Rose SR, Shulman D, I, Larsson P, Wakley LR, Wills S, Bakker B. Gender does not influence prepubertal growth velocity during standard growth hormone therapy - Analysis of United States KIGS data. J Pediatr Endocrinol Metab 2005; 18: 1045-1051. (Pubitemid 43019992)
83. Steinhausen HC, Dörr HG, Malin Z. Behavioral evaluation of GH treatment in short statured children and adolescents: Findings from a pilot study. J Endocrinol Invest 2002; 25: 351-356. (Pubitemid 34436131)
84. Wan L, Chen WC, Tsai Y, Kao YT, Hsieh YY, Lee CC, Tsai CH, Chen CP, Tsai FJ. Growth hormone (GH) receptor C.1319 G>T polymorphism, but not exon 3 retention or deletion is associated with better first-year growth response to GH therapy in patients with GH deficiency. Pediatr Res 2007; 62: 735-740.
85. Allemand D, Eiholzer U, Rousson V, Girard J, Blum- Werner, Torresani T, Gasser T. Increased adrenal androgen levels in patients with Prader-Willi syndrome are associated with insulin, IGF-I, and leptin, but not with measures of obesity. Horm Res 2002; 58: 215-222.
86. Craig ME, Cowell CT, Larsson P, Zipf WB, Reiter EO, Wikland KA, Ranke MB, Price DA. Growth hormone treatment and adverse events in Prader- Willi syndrome: Data from KIGS (the Pfizer International Growth Database). Clin Endocrinol 2006; 65: 178-185.
87. Eiholzer U, Grieser J, Schlumpf M, Allemand D. Clinical effects of treatment for hypogonadism in male adolescents with Prader-Labhart-Willi syndrome. Horm Res 2007; 68: 178-184.
88. Festen D-AM, de Weerd AW, van den Bossche R- AS, Joosten K, Hoeve H, Hokken-Koelega A-CS. Sleep-related breathing disorders in prepubertal children with Prader- Willi syndrome and effects of growth hormone treatment. J Clin Endocrinol Metab 2006; 91: 4911-4915.
89. Lindgren AC, Lindberg A. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: experience from KIGS (Pfizer International Growth Database). Horm Res 2008; 70: 182-187.
90. Schlumpf M, Eiholzer U, Gygax M, Schmid S, van dS, I, l'Allemand D. A daily comprehensive muscle training programme increases lean mass and spontaneous activity in children with Prader-Willi syndrome after 6 months. J Pediatr Endocrinol Metab 2006; 19: 65-74.
91. Bettendorf M, Doerr HG, Hauffa BP, Lindberg- Anders, Mehls O, Partsch CJ, Schwarz HP, Stahnke- Nikolaus, Ranke MB. Prevalence of autoantibodies associated with thyroid and celiac disease in Ullrich- Turner syndrome in relation to adult height after growth hormone treatment. J Pediatr Endocrinol Metab 2006; 19: 149-154.
92. Binder G, Baur F, Schweizer R, Ranke MB. The d3- growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in turner syndrome and short small-for-gestational-age children. J Clin Endocrinol Metab 2006; 91: 659-664.
93. Darendeliler F, Aycan Z, Cetinkaya E, Vidilisan S, Bas- Firdevs, Bideci A, Demirel F, Darcan S, Buyukgebiz- Atilla, Yildiz M, Berberoglu M, Arslanoglu I, Bundak- Ruveyde. Effects of growth hormone on growth, insulin resistance and related hormones (ghrelin, leptin and adiponectin) in Turner syndrome. Horm Res 2007; 68: 1-7.
94. Ito Y, Fujieda K, Tanaka T, Takano K, Chihara K, Seino Y, Irie M. Low-dose growth hormone treatment (0.175 mg/kg/week) for short stature in patients with Turner syndrome: Data from KIGS Japan. Endocr J 2006; 53: 699-703. (Pubitemid 44691025)
95. Ranke MB, Partsch CJ, Lindberg A, Dörr HG, Bettendorf M, Hauffa BP, Schwarz HP, Mehls O, Sander S, Stahnke N, Steinkamp H, Said E, Sippell W, Akkurt H, I, Andler W, Becker M, Böhles HJ, Brämswig J, Butenandt O, Enhrich J-HH, Erxleben B, Griefahn B, Grüters A, Hartmann K, Haverkamp F, Hecker W, Heinrich U, Hinkel GK, Hiort O, Holl R, Homoki J, Horneff G, Irle U, Jons R, Jourdan C, Keller E, Kerstan J, Korsch E, Kreuder J, Krohn HP, Krull F, Kunze D, Lakomek M, Lenz D, Leuthold U, Mix M, Mohnike K, Morlot M, Mühlenberg R, Müller H, Pavlovic M, Rager K, Rauh W, Rickers HJ, Schenk B, Schnabel D, Schönau E, Simic SG, Teufel M, Tillmann W, Tittel B, Tuschy U, Ullrich KP, von Petrikowsky W, Weber HP, Wesseler K, Willig RP, Wintgens J, Witsch M. Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: Results of the German IGLU follow-up study 2001. Eur J Endocrinol 2002; 147: 625-633.
96. Wasniewska M, De Luca F, Bergamaschi R, Maria P, Mazzanti L, Matarazzo P, Petri A, Crisafulli G, Salzano G, Lombardo F. Early treatment with GH alone in Turner syndrome: prepubertal catch-up growth and waning effect. Eur J Endocrinol 2004; 151: 567-572.
97. Nissel R, Lindberg A, Mehls O, Haffher D. Factors predicting the near-final height in growth hormone- treated children and adolescents with chronic kidney disease. J Clin Endocrinol Metab 2008; 93: 1359-1365.
98. Van Dyck M, Gyssels A, Proesmans W, Nijs J, Eeckels R. Growth hormone treatment enhances bone mineralisation in children with chronic renal failure. Eur J Pediatr 2001; 160: 359-363.
99. Zivicnjak M, Franke D, Filler G, Haffner D, Froede K, Nissel R, Haase S, Offner G, Ehrich J-HH, Querfeld U. Growth impairment shows an age- dependent pattern in boys with chronic kidney disease. Pediatr Nephrol 2007; 22: 420-429.
100. Bechtold S, Lang G, Butenandt O. Growth hormone therapy in children born small for gestational age: A 4-year follow-up study. Acta Paediatr Suppl 1997; 141. (Pubitemid 27254982)
101. Boguszewski M, Dahlgren J, Bjarnason R, Rosberg S, Carlsson LM, Carlsson B, Albertsson WK. Serum leptin in short children born small for gestational age: relationship with the growth response to growth hormone treatment. The Swedish Study Group for Growth Hormone Treatment. Eur J Endocrinol 1997; 137: 387-395.
102. Chatelain PG. Auxology and response to growth hormone treatment of patients with intrauterine growth retardation or Silver-Russell syndrome: Analysis of data from the Kabi Pharmacia International Growth Study. Acta Paediatr 1993; 82: 79-81. (Pubitemid 23293854)
103. Dahlgren J, Wikland KA. Final height in short children born small for gestational age treated with growth hormone. Pediatr Res 2005; 57: 216-222.
104. de Zegher F, Du CM, V, Heinrichs C, Maes M, De Schepper J, Craen M, Vanweser K, Malvaux P, Rosenfeld RG. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years. J Clin Endocrinol Metab 1999; 84: 1558-1561.
105. Leger J, Garel C, Fjellestad PA, Hassan M, Czernichow P. Human growth hormone treatment of short-stature children born small for gestational age: effect on muscle and adipose tissue mass during a 3- year treatment period and after 1 year's withdrawal. J Clin Endocrinol Metab 1998; 83: 3512-3516.
106. Visser-van BH, Geenen R, Looij J, Huisman J, Wit JM, Sinnema G. The views of young adults and their parents on hormone treatment for short stature in adolescence. Horm Res 2008; 69: 172-179. (Pubitemid 351161046)
107. Stabler B, Siegel PT, Clopper RR, Stoppani CE, Compton PG, Underwood LE. Behavior change after growth hormone treatment of children with short stature. J Pediatr 1998; 133: 366-373.
108. Voss LD, Mulligan J. The short normal child in school: self-esteem, behavior and attainment before puberty (The Wessex Growth Study). In: Stabler B, Underwood LE, eds. Growth, stature and adaptation. Chapel Hill: University of North Carolina, 1994; 47-64.
109. Rawlins M. De testimonio - on the evidence for decisions about the use of therapeutic interventions. Lancet 2008; 372: 2152-2161.
110. Higgins JPT, Green Se. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration. Available at: www.cochrane- handbook.org.